Viridian Therapeutics Files 8-K on Financials
Ticker: VRDN · Form: 8-K · Filed: Nov 5, 2025 · CIK: 1590750
Sentiment: neutral
Topics: financial-reporting, corporate-history
Related Tickers: VRDN
TL;DR
Viridian Therapeutics (VRDN) filed an 8-K on Nov 5, 2025, updating financials. Formerly Miragen/Signal Genetics.
AI Summary
Viridian Therapeutics, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
Why It Matters
This 8-K filing provides an update on Viridian Therapeutics' financial health and operational results, which is crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or significant events.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- November 5, 2025 (date) — Date of Report
- Miragen Therapeutics, Inc. (company) — Former Company Name
- Signal Genetics, Inc. (company) — Former Company Name
- 221 Crescent Street, Suite 103A, Waltham, MA 02453 (address) — Business and Mail Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Viridian Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filed?
This 8-K was filed on November 5, 2025.
What were Viridian Therapeutics' former company names?
Viridian Therapeutics, Inc. was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
Where is Viridian Therapeutics, Inc. located?
Viridian Therapeutics, Inc. is located at 221 Crescent Street, Suite 103A, Waltham, MA 02453.
What is the state of incorporation for Viridian Therapeutics, Inc.?
Viridian Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-11-05 07:09:22
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
Filing Documents
- d33707d8k.htm (8-K) — 24KB
- d33707dex991.htm (EX-99.1) — 88KB
- g33707g1105012700514.jpg (GRAPHIC) — 3KB
- 0001193125-25-265711.txt ( ) — 245KB
- vrdn-20251105.xsd (EX-101.SCH) — 3KB
- vrdn-20251105_lab.xml (EX-101.LAB) — 18KB
- vrdn-20251105_pre.xml (EX-101.PRE) — 11KB
- d33707d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press release, dated November 5, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: November 5, 2025 By: /s/ Stephen Mahoney Stephen Mahoney President and Chief Executive Officer